ProCE Banner Activity

How STRIDE-II Adds to the Art and Science of Treat-to-Target in IBD

Clinical Thought
With advances in novel biologic and small molecule treatment options, new diagnostics, and increasingly complex treatment algorithms, STRIDE-II extends on the previous STRIDE recommendations to help define reasonable treatment targets for IBD.

Released: May 05, 2021

Expiration: May 04, 2022

Share

Faculty

Bruce E. Sands

Bruce E. Sands, MD, MS

Dr. Burrill B. Crohn Professor of Medicine
Icahn School of Medicine at Mount Sinai
Chief, Division of Gastroenterology
Mount Sinai Health System
New York, New York

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

Bristol Myers Squibb

Faculty Disclosure

Primary Author

Bruce E. Sands, MD, MS

Dr. Burrill B. Crohn Professor of Medicine
Icahn School of Medicine at Mount Sinai
Chief, Division of Gastroenterology
Mount Sinai Health System
New York, New York

Bruce E. Sands, MD, MS, has disclosed that he has received consulting fees from Abivax, Arena, AstraZeneca, Bacainn, Boehringer Ingelheim, Boston Pharmaceuticals, Celltrion, Genentech, Gilead Sciences, GlaxoSmithKline, Index, Inotrem, Ironwood, Janssen, Kallyope, Lilly, Pfizer, Prometheus Biosciences, Prometheus Therapeutics, Surrozen, Takeda, Target RWE, USWM Enterprises, and Viela Bio and funds for research support from Theravance.